Unkovic Peter, Basuray Anupam
, Columbus, USA.
Curr Treat Options Cardiovasc Med. 2018 Apr 3;20(4):35. doi: 10.1007/s11936-018-0628-9.
This review explores key features and potential management controversies in two emerging populations in heart failure: heart failure with recovered ejection fraction (HF-recovered EF) and heart failure with mid-range ejection fraction (HFmrEF).
While HF-recovered EF patients have better outcomes than heart failure with reduced ejection fraction (HFrEF), they continue to have symptoms, persistent biomarker elevations, and abnormal outcomes suggesting a continued disease process. HFmrEF patients appear to have features of HFrEF and heart failure with preserved ejection fraction (HFpEF), but have a high prevalence of ischemic heart disease and may represent a transitory phase between the HFrEF and HFpEF. Management strategies have insufficient data to warrant standardization at this time. HF-recovered EF and HFmrEF represent new populations with unmet needs and expose the pitfalls of an EF basis for heart failure classification.
本综述探讨心力衰竭两个新兴群体的关键特征和潜在管理争议:射血分数恢复的心力衰竭(HF-恢复型EF)和射血分数中等范围的心力衰竭(HFmrEF)。
虽然HF-恢复型EF患者的预后优于射血分数降低的心力衰竭(HFrEF)患者,但他们仍有症状、生物标志物持续升高以及异常预后,提示疾病进程仍在继续。HFmrEF患者似乎具有HFrEF和射血分数保留的心力衰竭(HFpEF)的特征,但缺血性心脏病患病率高,可能代表HFrEF和HFpEF之间的一个过渡阶段。目前管理策略的数据不足,无法保证标准化。HF-恢复型EF和HFmrEF代表了有未满足需求的新群体,并暴露了以EF为基础进行心力衰竭分类的缺陷。